Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These ...

There are approx. 25+ key companies which are developing the therapies for Cutaneous T-cell lymphoma. The companies which have their Cutaneous T-cell lymphoma drug candidates in the most advanced ...

In October 2024, Topas Therapeutics announced positive topline results from its Phase IIa trial of TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune ...

Continuous research has led to new drug developments, particularly disease-modifying therapies (DMTs) that slow MS ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

This handbook contains a comprehensive collection of protocols to streamline imaging workflows and ensure reproducible ...

Monoclonal antibody design begins with identifying antibodies that bind to a specific target. One way to do this is to isolate antibody producing B-cells from human blood samples. Scientists then ...